DE69830249D1 - Zielgerichtete liposomen zur verabreichung von genen - Google Patents

Zielgerichtete liposomen zur verabreichung von genen

Info

Publication number
DE69830249D1
DE69830249D1 DE69830249T DE69830249T DE69830249D1 DE 69830249 D1 DE69830249 D1 DE 69830249D1 DE 69830249 T DE69830249 T DE 69830249T DE 69830249 T DE69830249 T DE 69830249T DE 69830249 D1 DE69830249 D1 DE 69830249D1
Authority
DE
Germany
Prior art keywords
genes
administration
targeted liposomes
virus
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69830249T
Other languages
English (en)
Other versions
DE69830249T2 (de
Inventor
Esther H Chang
Liang Xu
Kathleen Pirollo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of DE69830249D1 publication Critical patent/DE69830249D1/de
Application granted granted Critical
Publication of DE69830249T2 publication Critical patent/DE69830249T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
DE69830249T 1997-11-19 1998-11-19 Zielgerichtete liposomen zur verabreichung von genen Expired - Lifetime DE69830249T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6618897P 1997-11-19 1997-11-19
US66188P 1997-11-19
US8317598P 1998-04-27 1998-04-27
US83175P 1998-04-27
PCT/US1998/024657 WO1999025320A1 (en) 1997-11-19 1998-11-19 Targeted liposome gene delivery

Publications (2)

Publication Number Publication Date
DE69830249D1 true DE69830249D1 (de) 2005-06-23
DE69830249T2 DE69830249T2 (de) 2006-05-04

Family

ID=26746455

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69841536T Expired - Lifetime DE69841536D1 (de) 1997-11-19 1998-11-19 Zielgerichtete Liposomen zur Verabreichung von Genen
DE69830249T Expired - Lifetime DE69830249T2 (de) 1997-11-19 1998-11-19 Zielgerichtete liposomen zur verabreichung von genen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69841536T Expired - Lifetime DE69841536D1 (de) 1997-11-19 1998-11-19 Zielgerichtete Liposomen zur Verabreichung von Genen

Country Status (12)

Country Link
EP (2) EP1166775B1 (de)
JP (2) JP2001522871A (de)
CN (3) CN1616665B (de)
AT (2) ATE459340T1 (de)
AU (1) AU759164C (de)
CA (1) CA2308584C (de)
DE (2) DE69841536D1 (de)
DK (1) DK1166775T3 (de)
ES (1) ES2339421T3 (de)
HK (3) HK1035490A1 (de)
PT (1) PT1166775E (de)
WO (1) WO1999025320A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4799736B2 (ja) 1999-02-22 2011-10-26 ジョージタウン・ユニバーシティ 全身性遺伝子送達のための抗体フラグメント標的化イムノリポソーム
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
US9034329B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2004066908A2 (fr) * 2003-01-17 2004-08-12 Sanofi Pasteur Composition comprenant lipides cationiques et un polynucleotide ou un polpeptide et methode pour leur delivrance ciblee
EP1595142A4 (de) * 2003-01-28 2006-08-23 Univ Georgetown Verfahren zur evaluierung der wirksamkeit bestimmter krebsbehandlungen
CN1327899C (zh) * 2003-05-10 2007-07-25 彭朝晖 腺病毒载体与p53基因的基因重组体的应用
PL1633327T3 (pl) * 2003-06-04 2011-02-28 Univ Georgetown Sposób poprawienia stabilności i okresu trwałości kompleksów liposomowych
US8627821B2 (en) 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
JP5102630B2 (ja) * 2005-11-24 2012-12-19 ジェノミディア株式会社 改変パラミクソウイルスおよびその作製方法
WO2007142781A1 (en) 2006-05-15 2007-12-13 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
CN102133404B (zh) * 2011-03-23 2013-01-16 成都诺恩生物科技有限公司 一种肿瘤靶向治疗药物载体、其制备方法及其应用
CA2857604A1 (en) 2011-12-22 2013-06-27 Nuvo Research Gmbh Liposomal chlorite or chlorate compositions
EP2711000B1 (de) 2012-09-19 2019-04-03 Georgetown University Gezielt ausgerichtete Liposome
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
EP2968598B1 (de) 2013-03-14 2020-05-27 Georgetown University Behandlung für exposition gegenüber nervengas
EP3359197B1 (de) 2015-10-08 2021-03-10 University of Utah Research Foundation Verfahren und zusammensetzungen zur prävention oder behandlung von krebs
EP3538546A1 (de) 2016-11-14 2019-09-18 Novartis AG Zusammensetzungen, verfahren und therapeutische verwendungen im zusammenhang mit fusogenem protein minion

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635380A (en) * 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
BR9508951A (pt) * 1994-09-13 1999-04-06 Theratech Inc Liberação intracelular de agentes químicos para um tipo específico de célula
US20020051767A1 (en) * 1995-09-13 2002-05-02 Yawen L. Chiang Cancer treatment
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
EP0904100B1 (de) * 1996-02-09 2006-07-26 Pi-Wan Cheng Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen
JP3956402B2 (ja) * 1996-03-04 2007-08-08 日本油脂株式会社 アンホテリシンｂ運搬体

Also Published As

Publication number Publication date
EP1032369B1 (de) 2005-05-18
HK1045641A1 (en) 2002-12-06
ATE295722T1 (de) 2005-06-15
AU759164B2 (en) 2003-04-10
JP2010263920A (ja) 2010-11-25
CN1904055A (zh) 2007-01-31
HK1035490A1 (en) 2001-11-30
AU1464299A (en) 1999-06-07
DK1166775T3 (da) 2010-05-03
HK1045641B (zh) 2010-10-29
CN1616665A (zh) 2005-05-18
ATE459340T1 (de) 2010-03-15
CA2308584A1 (en) 1999-05-27
WO1999025320A1 (en) 1999-05-27
CA2308584C (en) 2011-07-19
JP2001522871A (ja) 2001-11-20
DE69830249T2 (de) 2006-05-04
EP1166775A3 (de) 2003-06-25
AU759164C (en) 2007-03-29
CN1191094C (zh) 2005-03-02
DE69841536D1 (de) 2010-04-15
HK1078608A1 (en) 2006-03-17
CN1286630A (zh) 2001-03-07
ES2339421T3 (es) 2010-05-20
PT1166775E (pt) 2010-04-16
EP1032369A1 (de) 2000-09-06
EP1166775A2 (de) 2002-01-02
CN1616665B (zh) 2010-10-06
EP1166775B1 (de) 2010-03-03

Similar Documents

Publication Publication Date Title
HK1078608A1 (en) Targeted liposome gene delivery
ATE273320T1 (de) Fusogene liposomen
ATE209902T1 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
ATE172636T1 (de) Liposomales verabreichungssystem für biologisch aktive stoffe
AU9676198A (en) Drug delivery and gene therapy delivery system
EP1005376A4 (de) Methoden und zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
DK0852490T3 (da) Emulsionsformuleringer til tilførsel af nukleinsyrer til celler
ATE288719T1 (de) Kontrollierte abgabe von pharmazeutika in der vorderen augenkammer
FI963103A (fi) Ei-virusvektori
TR199501635A1 (tr) Solunum yolu ile alinan terapötik preparatlar.
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
WO2003002142A8 (en) Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
WO2001080840A3 (en) Cytotoxic agents comprising single-stranded and/or looped dna
ATE322255T1 (de) Polyamid-oligomere
WO1998030709A3 (en) Non-immunogenic prodrugs and selectable markers for use in gene therapy
ATE391186T1 (de) Gezielte verabreichung von kuenstlichen genen
AU7758598A (en) Stable pharmaceutical administration forms of peptides, proteins and nucleic acids
AU4089899A (en) Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
ATE419833T1 (de) Modulares zielgerichtetes liposomales verabreichungssytem
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
ATE414100T1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
DE69704269D1 (de) Dendritische, lysinhaltige Polypeptide zur gezielten Arzneimittelabreichung
DE3673436D1 (de) Gene fuer biologisch aktive proteine.
WO1999065461A3 (en) Cationic amphiphile micellar complexes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition